Search

… Health Canada is updating the labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 vaccines Public advisory Seek medical … following symptoms after vaccination with the Janssen and Vaxzevria COVID-19 vaccines: unexplained bleeding, …

… AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of … affected AstraZeneca COVID-19 Vaccine, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular … AstraZeneca Canada Inc. COVISHIELD, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular …

… AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of … affected AstraZeneca COVID-19 Vaccine, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular … AstraZeneca Canada Inc. COVISHIELD, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular …

… COVISHIELD (manufactured by Serum Institute of India) and AstraZeneca COVID-19 VACCINE (manufactured by AstraZeneca) are ChAdOx1-S recombinant vaccines developed by AstraZeneca and … section). Products affected COVISHIELD, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular …

… Authorization of AstraZeneca COVID-19 Vaccine with English-only Vial and … information during the initial distribution of the AstraZeneca COVID-19 Vaccine. Audiences Healthcare … affected AstraZeneca COVID-19 Vaccine, COVID-19 Vaccine (ChAdOx1-S [recombinant]), 5 mL solution for intramuscular …

… Importation of AstraZeneca COVID-19 Vaccine with English-only Vial and … information during the initial distribution of the AstraZeneca COVID-19 Vaccine (US-labelled vaccine supplies) … and Supplier in Canada AstraZeneca COVID-19 Vaccine, (ChAdOx1-S [recombinant]) Suspension for Intramuscular …

… Adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine Starting date: March 11, 2021 … adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine, and would like to reassure … these events. To date, no adverse events related to the AstraZeneca COVID-19 vaccine, or the version manufactured by …

… and English on Health Canada’s Drug Product Database , at astrazeneca.ca , or by scanning the QR code on the global … and English on Health Canada’s Drug Product Database , at astrazeneca.ca , or by scanning the QR code on the global … taken by Health Canada Health Canada has worked with AstraZeneca Canada Inc. to prepare this alert for EVUSHELD. …

… Health Canada issues label change on the AstraZeneca and COVISHIELD COVID-19 vaccines Starting date: … number: RA-75389 Last updated: 2021-06-29 Summary Product: AstraZeneca and COVISHIELD COVID-19 vaccines Issue: Health … is updating the product monograph—or label—for the AstraZeneca and COVISHIELD COVID-19 vaccines to add capillary …

… and English on Health Canada’s Drug Product Database , at astrazeneca.ca , or by scanning the QR code on the global … and English on Health Canada’s Drug Product Database , at astrazeneca.ca , or by scanning the QR code on the global … taken by Health Canada Health Canada has worked with AstraZeneca Canada Inc. to prepare this alert for EVUSHELD. …

… EVUSHELD in the context of the global COVID-19 pandemic, AstraZeneca will distribute product vials and cartons with … recommended. In order to provide rapid access to EVUSHELD, AstraZeneca will distribute product vials and cartons with … Canadian Product Monograph (CPM), can be accessed at astrazeneca.ca , or by scanning the QR code on the global …

… - Important Safety Information on IRESSA (gefitinib) - AstraZeneca Canada Inc. Starting date: April 10, 2007 Posting … RA-19000556 This is duplicated text of a letter from AstraZeneca Canada Inc . Contact the company for a copy of … failed to prolong survival and increased bleeding events. AstraZeneca Canada Inc., in consultation with Health Canada, …

… Regarding Accolate® (Zafirlukast) and Hepatic Effects – AstraZeneca Starting date: December 18, 2002 Posting date: … RA-17000265 This is duplicated text of a letter from AstraZeneca. Contact the company for a copy of any … is estimated to be more than 1.5 million patient years. AstraZeneca Canada Inc. would like to update you on important …

… Safety Information on IRESSA® (gefitinib) 250 mg Tablets - AstraZeneca Canada Inc. Starting date: August 26, 2005 … RA-19000311 This is duplicated text of a letter from AstraZeneca Canada Inc. Contact the company for a copy of any … Safety Information on IRESSA (gefitinib) 250 mg Tablets AstraZeneca Canada Inc. 1004 Middlegate Road Mississauga …

… (rosuvastatin) with Muscle -Related Adverse Events – AstraZeneca Canada Inc. – For Health Professionals Starting … RA-17000985 This is duplicated text of a letter from AstraZeneca Canada Inc .Contact the company for a copy of any … CRESTOR ® (rosuvastatin) Dear Health Care Professional, AstraZeneca Canada Inc., in consultation with Health Canada, …